Țară: Singapore
Limbă: engleză
Sursă: HSA (Health Sciences Authority)
Sodium valproate
AGUETTANT ASIA PACIFIC PTE. LTD.
N03AG01
INJECTION, SOLUTION
Sodium valproate 400mg/4ml
INTRAVENOUS
Prescription Only
Laboratoire Aguettant
ACTIVE
2018-08-16
SODIUM VALPROATE AGUETTANT 400 MG/4 ML, SOLUTION FOR INJECTION ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT SODIUM VALPROATE AGUETTANT 400 MG/4 ML, SOLUTION FOR INJECTION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium valproate .......................................................................................................................... 400 mg Per 4 ml of solution for injection. This medicinal product contains sodium. Each mL of solution for injection contains 13.83 mg of sodium, equivalent to 0.60 of sodium. Each 4 mL ampoule contains 55.32 mg of sodium, equivalent to 2.41 mmol of sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear and colourless. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS The treatment of epileptic patients who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible. In the treatment of generalized or partial epilepsy, particularly with the following patterns of seizures: - absence - myoclonic - tonic-clonic - atonic - mixed As well as, for partial epilepsy: - simple or complex seizures - secondary generalized seizures - specific syndromes (West, Lennox-Gastaut) 4.2. POSOLOGY AND METHOD OF ADMINISTRATION SODIUM VALPROATE AGUETTANT may be given by direct slow intravenous injection or by infusion using a separate intravenous line in normal saline or dextrose 5%. _Epilepsy _ Daily dosage requirements vary according to age and body weight. SODIUM VALPROATE AGUETTANT should not be administered via the same IV line as other IV additives. The intravenous solution is suitable for infusion by PVC, polyethylene or glass containers. Patients already satisfactorily treated with SODIUM VALPROATE AGUETTANT may be continued at their Citiți documentul complet